Peter Mueller, Ph.D.
President of R&D and Chief Scientific Officer
Pronutria BioSciences LLC
In November 2014, Dr. Mueller joined Pronutria Biosciences LLC as the President of Research and Development & Chief Scientific Officer.
Prior to his time at Pronutria, Dr. Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals, starting there in 2003.
provided strategic oversight for Vertex's worldwide drug discovery and development programs.
was responsible to build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, Clinical and Non-Clinical Development, Regulatory and Medical Affairs as well as Patient Safety.
Key areas of Vertex' R&D
have been Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases.
leadership led in 2011 to the successful approval and launch of INCIVEK (HepC), and a NDA, MAA and numerous sNDA submission(s) for KALYDECO (CF) with the first approval in the US on January 31, 2012 followed by consecutive approvals in the EU, Canada and Australia.
Both Breakthrough Therapies got awarded the prestigious Prix Galien award (US, Telaprevir) or its European counterpart the Galenus Preis (Kalydeco).
The combination therapy lumacaftor/ivacaftor intended to treat the majority of Cystic fibrosis patients carrying the 508del mutation finished phase 3 successfully and entered into registration.
In addition, several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA) enhanced Vertex's drug pipeline as well as numerous preclinical candidates (MS, IBD, Cancer, TB).
Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for Research in North America and the Development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997.
played a key role in the development of Spiriva, Combivent and Atrovent.
also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis.
time with Boehringer Ingelheim
, starting there in 1984, Dr. Mueller
oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry.
completed fellowships in Quantum Pharmacology at Oxford University
and in Biophysics at Rochester University